Cytidine Analog RX-3117
An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, the cytidine analog RX-3117 is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, RX-3117 also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway. [ ]
Term info
Cytidine Analog RX-3117
- 4-Amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidin-2(1H)-one
- Cytidine Analog RX-3117
- Fluorocyclopentenylcytosine
- RX-3117
- TV-1360
NCIT_C116978, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712
865838-26-2
CTRP
Cytidine Analog RX-3117
747250
747250
Cytidine Analog RX-3117
Pharmacologic Substance, Nucleic Acid, Nucleoside, or Nucleotide
C3834251
C113444
Term relations
- Ribonucleotide Reductase Inhibitor
- Pyrimidine Antagonist
- Chemical_Or_Drug_Has_Physiologic_Effect some DNA Synthesis Inhibition
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Enzyme Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis
- Chemical_Or_Drug_Affects_Gene_Product some Ribonucleotide Reductase
- Chemical_Or_Drug_Has_Physiologic_Effect some Nucleotide Biosynthesis Process